



## **Emergent BioSolutions to Present at November Investor Conferences**

October 29, 2007

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 29, 2007--Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at two investor conferences during the month of November. The November conferences are:

- JPMorgan Ninth SMid Cap Conference  
Four Seasons Hotel  
Boston, MA.  
November 5, 2007  
Presentation Time: 1:20 pm Eastern
- Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference  
New York Palace Hotel  
New York, NY.  
November 7, 2007  
Presentation Time: 11:50 am Eastern

During these presentations, senior management will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

Webcasts of each of these presentations will be available both live and by replay. To access either the live or archived webcast for either presentation, please proceed to [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), click on the "Investors" link and proceed to the "Webcasts & Presentations" section, beginning on the day of the specific presentation.

An archived replay of each webcast will be available 24 hours after the live presentation.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

CONTACT: Emergent BioSolutions Inc.

Investors:

Robert G. Burrows  
Vice President, Investor Relations  
301-795-1877  
[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

Media:

Tracey Schmitt  
Director, Corporate Communications  
301-795-1800  
[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)

SOURCE: Emergent BioSolutions Inc.